| CAN1012 in Pre-Malignant DCIS and LCIS (NCT07408856) | Providence Health & Services | 2026-08-01 |
| CAN1012 in Pre-malignant Oral Dysplasia (NCT07620496) | Providence Health & Services | 2026-07-01 |
| A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies (NCT06719362) | Providence Health & Services | 2025-06-17 |
| Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients (NCT06353997) | Providence Health & Services | 2024-09-05 |
| Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (NCT06175000) | Providence Health & Services | 2024-03-13 |
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma (NCT05913388) | Providence Health & Services | 2024-02-29 |
| GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients (NCT04987996) | Providence Health & Services | 2023-07-01 |
| Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) (NCT05349890) | Providence Health & Services | 2023-04-03 |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors (NCT05249114) | Providence Health & Services | 2022-12-28 |
| Clinical Outcomes and Patient Satisfaction With Use of the Amma System (NCT05508984) | Providence Health & Services | 2022-08-22 |
| Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma (NCT05308901) | Providence Health & Services | 2022-08-02 |
| Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication (NCT04796584) | Providence Health & Services | 2022-07-11 |
| SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (NCT04417699) | Providence Health & Services | 2022-07-05 |
| Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma (NCT05200143) | Providence Health & Services | 2022-06-08 |
| Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) (NCT04520711) | Providence Health & Services | 2022-02-08 |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) (NCT04938609) | Providence Health & Services | 2022-01-11 |
| Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (NCT04896320) | Providence Health & Services | 2021-12-15 |
| Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis (NCT05077956) | Providence Health & Services | 2021-10-19 |
| Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer (NCT04895761) | Providence Health & Services | 2021-09-10 |
| Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (NCT04470024) | Providence Health & Services | 2021-08-05 |
| Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer (NCT04373031) | Providence Health & Services | 2020-12-30 |
| CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (NCT04627675) | Providence Health & Services | 2020-12-30 |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (NCT04061980) | Providence Health & Services | 2020-10-30 |
| A Systems Approach to Understanding Disease Processes in Multiple Sclerosis (NCT05081700) | Providence Health & Services | 2020-05-11 |
| Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care (NCT04334967) | Providence Health & Services | 2020-03-30 |
| Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab (NCT04175834) | Providence Health & Services | 2020-02-05 |
| Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM (NCT03705351) | Providence Health & Services | 2019-12-02 |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (NCT03650894) | Providence Health & Services | 2019-04-03 |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma (NCT03336606) | Providence Health & Services | 2018-07-25 |
| Melatonin in Patients With Multiple Sclerosis (MS). (NCT03498131) | Providence Health & Services | 2018-05-09 |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NCT03247712) | Providence Health & Services | 2018-01-15 |